GHRP-2 5mg

GHRP-2 5mg is a synthetic hexapeptide compound designed for research and laboratory use. This high-purity formulation delivers 5 milligrams of Growth Hormone Releasing Peptide-2, a potent growth hormone secretagogue that acts on the ghrelin receptor to stimulate endogenous growth hormone release, suitable for scientific investigation and experimental applications. Each vial is manufactured to exacting standards to ensure consistency and reliability in research settings. Ideal for qualified researchers and institutions exploring growth hormone axis regulation, metabolic function, and recovery pathway studies. Store in a cool, dry place away from direct light. For research purposes only.

Specifications: Active Ingredient: GHRP-2 (Growth Hormone Releasing Peptide-2) Concentration: 5mg per vial Purity: Research-grade Format: Lyophilized powder Storage: Cool, dry environment, 2–8°C (refrigerated) Shelf Life: Refer to batch documentation for expiration details Intended Use: Laboratory and research applications only Quality Standard: Manufactured to pharmaceutical-grade consistency protocols Suitable for qualified researchers, academic institutions, and licensed laboratories conducting growth hormone and metabolic peptide research.

Molecular Formula: C₄₅H₅₅N₉O₆ Molecular Weight: 817.98 g/mol CAS Number: 158861-67-7 Sequence: His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂ Sequence Classification: Synthetic hexapeptide; growth hormone secretagogue and ghrelin receptor agonist Mechanism: Stimulates pulsatile growth hormone release from the anterior pituitary via ghrelin receptor (GHSR-1a) activation, independent of GHRH pathways, without significantly affecting cortisol or prolactin levels Purity Analysis: ≥98% by HPLC This molecular data supports advanced research into growth hormone secretion mechanisms, IGF-1 axis modulation, and metabolic regulation studies.

Storage Before Reconstitution: Store the sealed vial at 2–8°C (refrigerated) or at room temperature (15–25°C) in a cool, dry place away from direct sunlight and heat sources. Keep in original packaging to protect from light exposure. Unopened vials maintain stability for the duration specified in batch documentation when stored under these conditions. Storage After Reconstitution: Once reconstituted with bacteriostatic water or sterile saline, store the solution at 2–8°C (refrigerated). Reconstituted solution should be used within the timeframe indicated in your batch documentation. Avoid repeated freeze-thaw cycles, which may compromise peptide integrity. Keep the vial upright and away from direct light during storage. General Handling: Maintain sterile technique during reconstitution. Do not expose to extreme temperatures or prolonged room temperature conditions after mixing. For research use only. Not intended for human or veterinary use.

Research References

The following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.

1. GHRP-2: Potency and GH Secretagogue Profile
   Bowers CY. (1998). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 54(12), 1316–1329. https://doi.org/10.1007/s000180050257
   Comprehensive review by the pioneer of GHRP research, characterising GHRP-2 as one of the most potent synthetic GH secretagogues, detailing its hexapeptide structure, GHS-R1a binding affinity, and comparative GH-releasing potency relative to GHRP-6 and other GHRPs.
2. GHRP-2 Dose–Response and GH/IGF-1 Axis Stimulation
   Arvat E, et al. (1997). GHRP-2, a synthetic hexapeptide, stimulates GH secretion in normal subjects and in patients with GH deficiency. Journal of Endocrinological Investigation, 20(3), 140–146. https://doi.org/10.1007/BF03347955
   Demonstrates dose-dependent GH stimulation by GHRP-2 in both healthy subjects and GH-deficient patients, with minimal effect on cortisol and prolactin, establishing its selectivity profile and providing key pharmacodynamic data for GH-axis research models.
3. GHRP-2 vs. GHRP-6: Comparative Selectivity and Cortisol Effects
   Ghigo E, et al. (1994). Growth hormone-releasing peptides. European Journal of Endocrinology, 131(5), 445–460. https://doi.org/10.1530/eje.0.1310445
   Comparative review of GHRP-2 and GHRP-6 pharmacology, demonstrating that GHRP-2 produces greater GH release with a more favourable cortisol and prolactin profile than GHRP-6, providing essential context for researchers selecting between GHS-R1a agonists for GH-axis studies.
4. GHS-R1a Receptor and GHRP-2 Binding Mechanism
   Howard AD, et al. (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science, 273(5277), 974–977. https://doi.org/10.1126/science.273.5277.974
   Reports the cloning and characterisation of GHS-R1a — the primary molecular target of GHRP-2 — establishing the receptor biology and signal transduction pathways through which GHRP-2 stimulates somatotroph GH secretion.
5. GHRP-2 and Cardioprotection: GH-Independent Effects
   Berlanga-Acosta J, et al. (2017). Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clinical Medicine Insights: Cardiology, 11, 1179546817694558. https://doi.org/10.1177/1179546817694558
   Reviews the GH-independent cytoprotective and cardioprotective effects of GHRP-2 and related secretagogues, covering anti-apoptotic, anti-inflammatory, and anti-fibrotic mechanisms observed in cardiac, hepatic, and renal tissue models — expanding the research scope beyond the GH axis.

All references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.